Rayno DX and Tools Mid Year Review and AACC Update: ABAX, ILMN, HOLX, TMO.. Update-2
Update -2 Aug. 1 Draft Guidance on LDTs Coming from FDA in 60 Days: Tests Must Be Validated More regulation coming means greater development costs and potential time delays for clinical tests in development and currently marketed as LDTs . Presumably LDT tests will be allowed to remain on the...
No Summer Doldrums In Biotech Today … PBYI…Update-1
Update 7/23 Biogen Idec (BIIB) Soars 11% on Earnings EPS at $3.49 vs est $2.83; Sales of MS drugs were $2.42B vs $1.72B last year. Our large cap portfolio is now up 15% YTD with less risk than mid and small caps. One analyst thinks PBYI will be acquired but watch out with a market cap near $7B...
FED Comments Focus On “Bubble” Stocks In Social Media and Biotech…. Update-1
Update 8PM EDT NASDAQ Holds Losses to 0.54%-Futures Stable Biotech Damage Across the Sector-Rayno Life Science Portfolio Notes Large Caps off about 2% (FBT), but Gilead (GILD) down only 0.95% and Roche (RHHBY) up 0.28%. Rayno Biopharma stocks all red down 3-4% with XBI down 3.86%, IBB down...
Tepid Rally Favors Large Caps: ABBV, GILD, RHHBY
Healthcare Stocks trail other sectors up 0.34%, Energy up 0.8%, Financials up 0.73% and Technology up 0.77% But biotech ETFs are in the Green Biotechnology stocks were mixed today with the following winners among our large cap picks: Gilead Sciences (GILD) up 1.26%, Roche Holding (RHHBY) up...
Risk Off: Take Profits in Biotech Stocks… Update -1
Re-iterate call from Tuesday....futures down 0.8%-Russell down 2%, gold up, Japan and Europe down.. Bad Tape Yesterday (7/7) Calls For Raising Cash NASDAQ at 4451 up 6.58% YTD Major ETFs and Fidelity (FBIOX) take a ~3% hit All major market sectors weak with healthcare down 1% Unusual weakness...